Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation

Curcumin Inhibits Constitutive STAT3 Phosphorylation in Human Pancreatic Cancer Cell lines and Downregulation of Survivin/BIRC5 Gene Expression

(2010) W. Glienke et al.   CANCER INVESTIGATION

Cucurbitacin B Induces Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcitabine on Pancreatic Cancer Cells

(2009) N. H. Thoennissen et al.   CANCER RESEARCH

Signaling Through Rho GTPase Pathway as Viable Drug Target

(2009) Qun Lu et al.   CURRENT MEDICINAL CHEMISTRY

δ-Catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profiles

(2009) Yan Zeng et al.   Molecular Cancer

Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: The role of p53 and p21

(2008) José M. Escandell et al.   BIOCHEMICAL PHARMACOLOGY

Cell Type Variation in Responses to Antimitotic Drugs that Target Microtubules and Kinesin-5

(2008) J. Shi et al.   CANCER RESEARCH

Actin-Aggregating Cucurbitacins fromPhysocarpus capitatus

(2008) Katherine N. Maloney et al.   JOURNAL OF NATURAL PRODUCTS

Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells

(2008) Talin Haritunians et al.   LEUKEMIA RESEARCH

Ras oncogenes: split personalities

(2008) Antoine E. Karnoub et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY